ADA 2021 | The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes | diabetes.medicinematters.com Skip to main content

06-29-2021 | ADA 2021 | Conference coverage | Video

The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes

share
SHARE

John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic (3:58).

Related content

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity